FDA Docket · In progress
Comment on peptide compounding
Our submission to docket FDA-2025-N-6895 on standards-based access, ahead of the July 2026 advisory meeting.
We’re a Council of operators, doctors, and researchers dedicated to safe standards and practices for the American peptide and therapeutic industry.
In addition to advocating for safe, effective, track-and-traced American APIs, we also set the standard, test the market, and publish what we find.
Health freedom delivered in practice with safe, physician-supervised access to therapies Americans already use and demand pulled out of the gray market instead of driven underground.
Domestic, cGMP, track-and-traced ingredient, reshoring a supply chain now dominated by unregulated foreign powder. A patient-safety win and a supply-chain-security win at once.
We publish comparative analytical data on what the market is actually selling, with transparent, disclosed methods.
We set the standard, we test the market, and we publish what we find.
Our first independent results, across several peptide providers, post in under two weeks.
We are currently fielding independent testing across several providers of peptides. We will publish the full results in under two weeks.
A product you can’t trace is a product you can’t trust. This is the case for 100% track and trace, in data.
One standard for the whole industry. Every batch, from synthesis to patient, documented and verifiable. Not a feature of a few responsible operators. The bar for all of them.
Every member company adopts this standard as a condition of membership: American, cGMP, independently tested, honestly labeled, and track-and-traced from ingredient to patient. A commitment made in the open, not a private promise.
Each one adopts it in public. Membership is open to any operator that meets the bar.
cGMP manufacture in FDA-registered facilities, with defined identity and purity specifications, characterized impurities, and a certificate of analysis on every lot.
Validated analytical methods run by accredited, third-party laboratories. Every lot verified, results published, and methods disclosed.
USP <795>, <797>, and <800> applied to peptides: documented, repeatable processes, sterility and environmental controls, and beyond-use dating.
Full chain of custody with DSCSA-aligned documentation, controlled storage and handling, and working recall procedures.
A real clinical evaluation, informed consent, baseline and monitoring labs, and adverse-event reporting.
A bona fide patient-clinician relationship, verified identity, clear prescribing protocols, and continuity of care.
The FDA’s compounding advisory committee reviews the first peptides for the legal compounding list on July 23–24, 2026. We’re at the table, with the data and the standards to keep it safe, legal, and American.
Where we standWomen’s vitality, menopause, and hormonal health have been underserved for too long. We’re building a safe, supervised, American-made path, on a published standard our members commit to, led by the women building this industry.
Women’s health →Join a movement of patients, practitioners, and responsible operators.
Americans are already using peptide therapies. The only real question is where: in a regulated, quality-controlled, American-made channel, or in the shadows. We stand for the first.
Peptide therapeutics have entered the mainstream — a $50 billion-plus global market with more than 100 FDA-approved drugs — and the demand is real.
Much of it today is met by an unregulated gray market built on anonymous, largely foreign-sourced material with no oversight, no chain of custody, and no accountability when something goes wrong. The scale shows in the GLP-1 boom: with brand-name versions near $1,300 a month and compounded versions near $150, millions of Americans have turned to compounded and gray-market sources.
Prohibition does not fix this. It leaves the demand exactly where it is and pushes the supply further into the dark, where the risk runs highest. The responsible path runs the other way: bring this category into a legal, supervised, quality-controlled channel built on American manufacturing, independent testing, and published data, so patients and their physicians can make health choices with confidence.
That is the decision in front of regulators and lawmakers today. The live choice is between a verified American channel and an unregulated foreign one. We stand for the verified one, and we are ready to help build it.
Access and safety are not opposing goals. They are the same goal.
Health freedom delivered in practice with safe, physician-supervised access to therapies Americans already use and demand pulled out of the gray market instead of driven underground.
Domestic, cGMP, track-and-traced ingredient, reshoring a supply chain now dominated by unregulated foreign powder. A patient-safety win and a supply-chain-security win at once.
We publish comparative analytical data on what the market is actually selling, with transparent, disclosed methods.
Six positions, one principle: bring peptide therapy into a legal, supervised, American-made channel, on a standard the whole industry can be held to.
Add the priority peptides to the appropriate compounding lists through the established FDA process, with quality and provenance conditions attached.
cGMP-manufactured ingredients, certificates of analysis, independent testing, honest labeling, and documented chain of custody from synthesis to patient.
100% track & tracePolicy that strengthens domestic ingredient production and reduces dependence on unregulated foreign supply.
Preserve the physician-supervised prescribing model, including women’s health applications, where it operates within clear clinical standards.
Pursue the unregulated and mislabeled gray-market supply that puts patients at risk. We will help identify it.
Defend responsible, compliantly-sourced operators against enforcement that targets paperwork over genuine patient risk.
Our submission to docket FDA-2025-N-6895 on standards-based access, ahead of the July 2026 advisory meeting.
To the agencies and offices shaping API policy.
The council’s public statement of purpose and principle.
See the evidence behind the position, or add your voice.
The council’s formal comment for the Pharmacy Compounding Advisory Committee, on the peptides under review for the Section 503A Bulks List at the July 23–24, 2026 meeting. Our position is simple: legal access, on the condition of quality, provenance, and traceability.
Submitted to the public docket via Regulations.gov.
Pharmacy Compounding Advisory Committee, FDA White Oak Campus, Silver Spring, MD.
Comments received by this date are provided to committee members in advance. The docket closes July 22.
The American Council of Peptides submits this comment on the peptide bulk drug substances under review for the Section 503A Bulk Drug Substances List.
ACOP is an alliance of responsible manufacturers, compounding pharmacies, clinicians, telehealth providers, and accredited testing laboratories. Our members make and provide these therapies; the council publishes the standard they commit to, tests what the market is selling, and publishes what we find. Our interest in this proceeding is singular: that Americans who use these therapies do so through a legal, supervised, quality-controlled, and traceable channel rather than an unregulated one.
We take no position on the clinical efficacy of any individual substance before the Committee. Those determinations belong to the Committee and to the evidentiary record. Our comment concerns the regulatory framework, product quality, supply-chain integrity, and patient safety — the conditions under which any compounding the Committee may recommend should occur.
The peptides under review are already in widespread use across the United States. Hundreds of thousands of patients obtain them today, overwhelmingly through a gray market of online sellers and unregistered sources. The question before the Committee is not whether Americans will use these substances. It is whether that use happens in a regulated channel that can be held to a standard, or an unregulated one that cannot.
Prohibition does not remove the demand. It relocates the supply to its least accountable form. A decision that forecloses a lawful 503A pathway will not end use of these peptides; it will continue to route patients to anonymous product of unknown origin, composition, and purity. The safer course is to bring this category into a supervised, quality-controlled channel and attach meaningful conditions to it.
Independent testing bought semaglutide from three online sellers and measured it against the 99% purity printed on the label.
This is the supply patients turn to in the absence of a regulated channel: under-dosed, over-dosed, and contaminated, often in the same market. The harm signal is rising alongside demand. An analysis of the FDA’s own adverse-event system by KFF Health News found reported GLP-1 medication errors climbing from roughly 2,000 in 2020 to more than 25,000 in 2025, and FDA has warned about unapproved “research use” peptide products sold online and fraudulent labeling. These data do not speak to the merits of any peptide. They speak to the danger of leaving demand to an unregulated market.
Where the Committee finds a substance appropriate for compounding, we urge it to frame the recommendation around the quality and provenance of the bulk substance, not the substance alone:
Supply-chain integrity is part of the patient-safety picture. The bulk active ingredient that drives the gray market is overwhelmingly foreign-sourced and unverified; by volume, China is the single largest source of U.S. drug inputs, and the share of new active-ingredient manufacturing records filed domestically has fallen to a small fraction of the global total. Federal track-and-trace law reaches finished prescription drugs but not the bulk ingredient they are built from. Any durable framework for legal peptide compounding should encourage American, cGMP, traceable ingredient and work to close that gap. The need for a quality, GMP-compliant ingredient base to underpin any expansion of peptide compounding has been echoed across the compounding community, and we share it.
For any substance found appropriate, recommend inclusion on the 503A Bulks List subject to explicit quality conditions: cGMP-manufactured ingredient, defined specifications, independent lot testing, full chain of custody, and accurate labeling.
Recommend that compounding occur within a bona fide patient-clinician relationship, with informed consent, appropriate baseline and monitoring evaluation, and adverse-event reporting.
Encourage FDA to support domestic, traceable active-ingredient supply and to address the traceability gap for bulk ingredient.
Recognize that a lawful, quality-controlled pathway is a patient-safety improvement over the unregulated market that will otherwise continue to serve this demand.
Comments received by July 9, 2026 reach the committee directly. We make it easy to weigh in.
We publish the standards the industry should meet, test what’s being sold against them, and report what we find. It points to one answer: 100% track and trace.
We set the standard, we test the market, and we publish what we find.
Not vague principles — the actual requirements an operator must meet to be considered responsible.
Every report publishes with its full methodology, open to anyone. Tests include purity, toxicity, and more.
We are currently fielding independent testing across several providers of peptides. We will publish the full results in under two weeks.
Established methods, specified in advance, published in full.
Accredited third parties, not the operators under review.
Documented sourcing, with the limits of each study stated.
If a sample tests clean, we publish that as well.
Each report will carry its full methodology, open to anyone.
What’s actually in the samples sold online, against what they claim. Full results in under two weeks.
Stated versus measured dose across a representative market sample. Protocol in design.
The supply-chain and patient-safety argument, on the evidence. Outline in development.
See where the council stands, or stand with us.
We publish the standard responsible peptide companies should meet. It is the platform we advocate for, and the commitment every member makes.
One standard for the whole industry. Every batch, from synthesis to patient, documented and verifiable. Not a feature of a few responsible operators. The bar for all of them.
Every member company adopts this standard as a condition of membership: American, cGMP, independently tested, honestly labeled, and track-and-traced from ingredient to patient. A commitment made in the open, not a private promise.
Objective, voluntary, and open to any operator that meets them. Full criteria, link by link, on The Proof.
Membership is open to any operator that meets it. Members adopt the standard in full, in public, for their part of the chain.
cGMP production, defined identity and purity specifications, characterized impurities, and a certificate of analysis on every lot.
Lots tested by accredited third-party laboratories, with results published and methods disclosed.
Full chain of custody on every batch, so any product can be traced from synthesis to the person who receives it.
Members hold to the standard as a condition of membership, disclose conflicts, keep claims discipline, and report when a lot falls short.
Each one adopts it in public, for its part of the chain. Membership is open to any operator that meets the bar.
Membership is how the field earns the right to legal, lasting access.
Membership in the Council is a public commitment to the standard we publish. Every member signs the same one-page letter. Once they do, they join the directory and display the member mark.
The member mark is not a product seal, and it is not a grade from the Council. It is a public statement that a company has signed the commitment and holds to it. Signed in the open, listed in public, and withdrawn if the commitment is broken.
Granted on signing. Held for as long as the commitment holds.
An authorized officer signs the one-page member commitment, the same letter every member signs, for your part of the chain.
The Council lists your company in the public member directory, by name and category, as a signatory to the standard.
You display the member mark. It says you have made the commitment and that you hold to it.
The full language is in the member commitment letter. The standard behind it is published in full.
Meet the ACOP standard for your part of the chain, ingredient to patient, and keep meeting it.
cGMP practice, defined specifications, characterized impurities, and a certificate of analysis on every lot.
Accredited third-party lot testing, with results published and methods disclosed.
State what is in the product and what is not. No claim of clinical efficacy for any peptide.
A documented chain of custody on every batch, and real clinical care wherever care is provided.
Disclose conflicts of interest, report when something falls short, and put it right.
The gray market makes promises no one signs. Our members sign theirs.
Apply to join, sign the letter, and display the mark.
The unregulated market runs on anonymous, foreign-sourced material that can’t be traced, tested, or stood behind. We’re calling for the opposite: ingredients made in registered, inspected American facilities, accountable from synthesis to patient.
Most gray-market peptide supply today is foreign-sourced, produced without oversight, and sold with no chain of custody.
When something goes wrong, there is no one to hold accountable and no way to trace what happened. Domestic manufacturing changes the equation. An ingredient made in an FDA-registered, inspected, cGMP facility can be identified, tested, documented, and recalled. That is the difference between a supply chain you can audit and one you cannot.
This is a public-health and supply-chain-security question before it is an economic one. A country that cannot trace the medicines its citizens take has a problem that tariffs and slogans do not solve. Provenance does.
A medicine you can’t trace is a medicine you can’t trust.
Federal law traces finished prescription drugs. It does not reach the bulk active ingredient those products are built from. That is the lane the gray market drives through.
Serialized and traced through the supply chain under the Drug Supply Chain Security Act.
Active pharmaceutical ingredients are exempt from DSCSA tracing. Foreign, unregulated material can enter with no documented origin.
Share of new active pharmaceutical ingredient master files filed with the FDA in 2024, by country of manufacturer.
Documented origin and lot-linked records from synthesis onward. You can see where it came from and what’s in it.
A real, registered, inspected entity stands behind the product, and answers for it if something goes wrong.
A domestic supply chain is a public-health and national-security asset, not a dependency on supply we don’t control.
The concern is not where a manufacturer is from. It is that unregulated, unverified supply, wherever it originates, cannot be traced, tested, or stood behind. Today that supply comes predominantly from overseas — China is the largest single source of US drug inputs by volume — which makes domestic, traceable production a public-health answer as much as an economic one.
We hold every operator, domestic or foreign, to the same standard: identity, purity, provenance, and a documented chain of custody. The passport doesn’t earn the trust. The proof does.
See where the council stands, or stand with us.
Women’s vitality, menopause, and hormonal health have been dismissed and underserved for too long. We’re building a safe, supervised, American-made path, on a published standard our members commit to.
For too long, women’s health beyond fertility has been an afterthought — under-researched, under-funded, and too often met with a shrug.
Women are 50.5% of the population, yet female-specific conditions receive only about 5% of medication research spending, and just 8.8% of NIH grant funding went to women’s health over the last decade. The result is a generation of women managing menopause, hormonal health, and vitality with too few good options and too little good information. The gray market rushed into that gap.
We’re proposing something better: a legal, supervised, American-made path, held to the same verified standard as everything else we stand behind. This work is led by the women building this industry, because the people most failed by the status quo should set the terms of what replaces it.
Women as a share of the US population, against female-specific conditions as a share of medication research spending.
Half the market. A fraction of the attention. We’re changing that.
A real clinical relationship, not a checkout cart. Screening, informed consent, and monitoring.
The same standard we hold everywhere: identity, purity, provenance, independent testing.
Evidence generated with women in mind, and published openly.
We’re a council of responsible operators, clinicians, and scientists, the companies and people building this industry. We publish the standard our members commit to, test the market, and advocate for safe, legal, American-made access.
The peptide field grew faster than the rules around it.
The result is a gap between a legitimate, quality-driven industry and an unregulated gray market that trades on the same names. We exist to make that difference visible, and to hold our members to a standard the gray market cannot meet.
We are not a marketing group and we are not a single company. We are a council: responsible manufacturers, pharmacies, clinicians, testing labs, telehealth providers, and the patients they serve, organized around rigorous standards.
Our testing and our findings answer to the evidence, not to any member.
Validated methods, accredited labs, published data. We show our work.
A real, named, answerable industry. The opposite of the gray market.
We disclose our funding, our members, and our methods.
The trade body: it publishes the standard, runs membership, and advocates for the policy agenda.
An affiliated nonprofit housing the market-testing program, research, and public education, structured to keep the science independent of commercial interest.
A separate political arm for direct advocacy, funded and disclosed transparently.
The Council is led by founders, clinicians, and researchers who put their names and their companies behind this standard.
They will be introduced with our founding announcement. Accountability is the point: the people responsible for the standard are visible and answerable, the opposite of the market we exist to replace.
Manufacturers, pharmacies, clinics, and testing labs. Logos and names listed once finalized.
See the standard, or where the council stands.
Membership is open to any operator willing to meet the standard and prove it. It is earned through verification, not bought.
If you manufacture, test, compound, distribute, prescribe, or deliver peptide therapeutics responsibly, the council is how you separate yourself from the gray market — and how the field earns the right to legal, lasting access.
cGMP API producers committed to identity, purity, and provenance.
503A / 503B operators meeting USP standards for peptides.
Prescribers and platforms operating real, supervised care.
Accredited labs and service providers that test the chain.
Dues disclosed and tiered by organization; details on application.
Safe, legal, American-made access won’t happen on its own. It happens when patients, clinicians, and responsible companies show up. Here’s how.
Add your name. We’ll keep you posted on the moments that matter and the ways to weigh in.
If safe access matters to you or your patients, your story is the most persuasive thing in the room.
When the moment comes, we’ll make it easy to be heard by the people deciding.
Prefer email? Write to members@americancouncilofpeptides.org.
Movements are won by the people who show up.
If you manufacture, compound, prescribe, or test, there’s a place for you.
Our statements, filings, findings, and press. Published here as they happen.
The council’s public launch.
Our formal submission to docket FDA-2025-N-6895 on standards-based access, ahead of the July 23–24, 2026 advisory meeting.
Gray-market purity & contamination.
Whether you’re a patient, a policymaker, a reporter, or an operator who meets the bar, here’s how to reach us.
Reach any desk using the form below.